期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

经吸入给药的抗菌药物药代动力学研究进展 被引量：3

原文传递
导出
摘要 随着院内感染中多药耐药（MDR）病原体的日益增多,肺部感染的治疗变得极为棘手,尤其是合并机械通气、囊纤维化及支气管扩张等的重症患者.传统的治疗方案主要为静脉给予敏感的抗菌药物,但多黏菌素和氨基糖苷类等药物往往由于治疗窗窄,肺穿透能力差,难以达到有效的肺组织浓度,疗效较差.近年来采用的吸入给药方式不仅可提高抗菌药物的肺组织浓度,还可降低抗菌药物的系统暴露水平[1],从而在增加疗效的同时减少全身不良反应的发生.
作者 顾永丽 孙增先
机构地区 连云港市第一人民医院药学部
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2016年第2期122-127,共6页 Chinese Journal of Tuberculosis and Respiratory Diseases
关键词 抗菌药物 力学研究 吸入给药 肺部感染 药代 全身不良反应 治疗方案 组织浓度
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献55

  • 1刘小媛,王导新.关于雾化吸入抗生素对呼吸机相关性肺炎的治疗[J].国际呼吸杂志,2012,32(24):1881-1884. 被引量：5
  • 2Nightingale SL. From the food and drug administration [ J ]. JAMA, 1998,279(9) :645.
  • 3Niederman MS, Chastre J, Corkery K, et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia [J]. Intensive Care Med,2012,38(2) :263-271.
  • 4Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group [ J ]. N Engl J Med, 1999,340 ( 1 ) : 23 -30.
  • 5Geller DE, Piflick WH, Nardella PA, et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis [J]. Chest,2002,122( 1 ) :219-226.
  • 6Wilson J, Moorehead L, Montgomery B. A phase 1 placebo- controlled, double-blind, randomized trial evaluating the safety and pharmacokinetics of three escalating doses of fosfomycin/ tobramycin for inhalation (FTI) in healthy volunteers[J].Pediatr Pulmono1,2008 ,43 :321.
  • 7de Velde F, Emonts M, Verbruggen S, et al. High tobramycin serum concentrations after tobramycin inhalation in a child with renal failure [ J ]. J Antimicrob Chemother, 2014,69 ( 11 ) : 3163- 3164.
  • 8Redmann S, Wainwright C, Staeey S, et al. Misleading high tobramycin plasma concentrations can be caused by skin contamination of fingerprick blood following inhalation of nebulizedtobramycin (TOBI) : a short report[ J]. Ther Drug Monit,2005, 27(2) :205-207.
  • 9Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections [ J ]. J Antimicrob Chemother,2008,61 (4) :859-868.
  • 10Clancy JP, Dupont L, Konstan MW, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection[J].Thorax,2013,68(9) :818-825.

二级参考文献46

  • 1Palmer LB. Aerosolized antibiotics in critically ill ventilated patients. Curr Opin Crit Care,2009,15:413-418.
  • 2Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid vs vaneomycin in ventilator-associated pneumonia due to methieillin-resistant Staphylococcus aureus. Chest, 2008,134 : 1200-1207.
  • 3Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med, 2008,36..2008-2013.
  • 4Le Conte P, Potel G, Peltier P, et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis, 1993,147 : 1279-1282.
  • 5Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis, 1987,136 : 1445-1449.
  • 6King P, Lomovskaya O, Griffith DC, et al. In vitro pharmaeodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother, 2010,54 : 143-148.
  • 7Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med, 2011, 183 :1510-1516.
  • 8Luyt CE, Clavel M, Guntupalli K, et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care, 2009,13 : R200.
  • 9Dhand R, Sohal H. Pulmonary Drug Delivery System for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices, 2008,5 : 9-18.
  • 10Eachempati SR, Hydo LJ, Shou J, et al. Does de-escalation ot antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma, 2009,66 : 1343-1348.

共引文献10

同被引文献26

引证文献3

二级引证文献12

中华结核和呼吸杂志
2016年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部